Zurück zu Ihrem Suchergebnis

Beschreibung

A potent and selective inhibitor of cyclin-dependent kinases (Cdks). Exhibits greater inhibitory potency compared to olomoucine (Cat. No. 495620). Inhibits p34 Cdc2/cyclin B (IC50 = 650 nM), p33 Cdk2/cyclin A (IC50 = 700 nM), p33 Cdk2/cyclin E (IC50 = 700 nM), and p33 Cdk2/p35 (IC50 = 200 nM) by competing for the ATP binding domain of these kinases. Exhibits very low sensitivity towards related kinases, such as Erk1 and Erk2 (IC50 = 34 µ,M and 14 µ,M, respectively). Roscovitine does not significantly affect the activity of other protein kinases even at 100 µ,M and compared to olomoucine, roscovitine displays increased anti-mitotic activity at the G1/S and G2/M phases of the cell cycle.